FDA Determines Regulatory Review Period for SPIRIVA HANDIHALER Patent Extension

Summary

The Food and Drug Administration (FDA) has determined the regulatory review period for the patent extension of SPIRIVA HANDIHALER, a human drug product, and is publishing this notice as required by law. The FDA made this determination due to the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of the patent.